Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma, Endometrial Stromal × selurampanel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gynecologic 1 Endocrine 1

Conditions

Sarcoma, Endometrial Stromal 1 Adrenocortical Adenoma 1

Interventions

selurampanel 1 Postmortem Imaging 1 Magnetic Resonance Spectroscopy 1 Imatinib Mesylate 1 High-Energy Shock Waves 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed

59 enrolled 6 charts

EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡